Arbutus Posts $164.6M H1 Profit on Moderna Settlement, Plans $230M Buyback
ABUS sits 36% above its 52-week low of $3.31.
Summary
Arbutus Biopharma reported Q2 2026 results with a $5.1M net loss but a $164.6M H1 profit driven by the $178.4M Moderna settlement payment received in July. Cash stands at $92.6M after $14.1M in operating use. The company plans to return up to $230M to shareholders via buybacks starting Q3, potentially through a Dutch auction tender offer. Additionally, Arbutus filed three international patent suits against Pfizer/BioNTech and gained FDA alignment on a Phase 2b trial design for its hepatitis B drug imdusiran, which also received Fast Track designation. The buyback and litigation moves signal aggressive capital deployment and IP enforcement following the Moderna windfall.
At the time of this announcement, ABUS was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $922.5M. The 52-week trading range was $3.31 to $5.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.